Displaying 675 (all) recruiting clinical trials.
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ...Phase
Interventional
-
A SINGLE-CENTER OBSERVATIONAL STUDY OF THE IMPACT OF TREMOR AFFECTING THE VOICE ON DEGLUTITION
Tremor affects ~1% of the global population or nearly 80 million people. In spite of this staggering figure, both nomenclature and treatment approaches are inconsistent ...Phase N/A
Non-Interventional
-
Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort (Multi-Center PAMPA Study)
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. Population ...Phase
Interventional
-
Effects of MRI Acceleration: Comparison with the Current NYU Standard
Magnetic resonance imaging can be acquired in different fashions. In recent times, a premium has been put on acceleration for various reasons, including patient comfort ...Phase
Interventional
-
Technical Software Development on Ultra-Low Field MRI
In this technical developmental study, we aim (i) to evaluate the hypothesis that ultra-low field MRI systems can produce images with meaningful structural and physiological ...Phase N/A Non-Interventional
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
DAY101 is an oral, selective, small-molecule, Type II pan-RAF kinase inhibitor that is being developed by DOT Therapeutics-1 Inc. (Day One, the Sponsor) for the ...Phase
Interventional
-
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
CompassHER2 RD (A011801) is a randomized trial in patients with residual disease after a predefined course of neoadjuvant HER2-directed treatment. While CompassHER2 RD allows entry ...Phase
Interventional
-
AN EIGHTEEN MONTH OBSERVATIONAL INVESTIGATION OF PARTICIPANTS WITH OPEN ANGLE GLAUCOMA AND A DOCUMENTED HISTORY OF PROGRESSIVE VISUAL FIELD LOSS: ASSESSING THE REPRODUCIBILITY AND RESPONSIVENESS OF OUTCOME MEASURES OF GLAUCOMA PROGRESSION
This is a 18 month observational study in individuals who have any form of open angle glaucoma with Humphrey visual field (HVF) 24-2 SITA standard ...Phase N/A Non-Interventional
-
The ConsideRAte study. A multipart exploratory study to evaluate splenic nerve stimulation in patients with rheumatoid arthritis.
The ConsideRAte study This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with an active implantable medical device ...Phase N/A Interventional
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific ...Phase
Interventional
